Weight-Loss Peptides: What Actually Works, and What Only Supports the Process

The peptides that most clearly drive weight loss are GLP-1 pathway medicines: semaglutide and tirzepatide. In large trials of the active ingredients, semaglutide produced about 15% mean body-weight loss and tirzepatide produced up to about 21% mean loss 1, 2. Other peptides mainly support body composition or specific fat-pattern problems.

What are peptides, and why are so many marketed for weight loss?

Peptides are short chains of amino acids. Some act like body signals, telling cells to release hormones, slow digestion, change appetite, or repair tissue.

That broad biology is why the word “peptide” gets used for very different products. GLP-1 receptor agonists like semaglutide are peptide-based medicines with large obesity trials. Growth-hormone peptides like sermorelin are different: they may change hormone signaling, but they have not shown the same weight-loss effect in large obesity studies 1, 6.

The key question is not “is it a peptide?” It is: what receptor does it act on, what human trials support it, what risks does it carry, and is it being prescribed through a licensed medical pathway?

Which peptides actually cause weight loss?

Semaglutide and tirzepatide have the strongest evidence for weight loss because they act on appetite regulation, fullness, and gastric emptying. In trials, the active ingredients were studied alongside lifestyle counseling, and individual results varied 1, 2.

Semaglutide (GLP-1)

Semaglutide is the active ingredient in Wegovy and Ozempic, and it is also available as compounded semaglutide via licensed 503A pharmacies, a non-FDA-approved compounded medication. Wegovy is FDA-approved for chronic weight management at a maintenance dose of 2.4 mg once weekly after dose escalation, while Ozempic is FDA-approved for type 2 diabetes, not general weight loss 3, 11.

Mechanism matters. Semaglutide mimics GLP-1, a gut hormone that helps the brain sense fullness, slows stomach emptying, and supports glucose-dependent insulin release 3. In STEP 1, adults with obesity or overweight without diabetes received semaglutide 2.4 mg once weekly and had 14.9% mean weight loss at 68 weeks, versus 2.4% with placebo 1. Results are not established for compounded formulations.

The same section needs the trade-offs. Common semaglutide side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain. The FDA label warns about risks including pancreatitis, gallbladder disease, kidney injury related to dehydration, increased heart rate, and a boxed warning about thyroid C-cell tumors based on rodent data; it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 3.

Tirzepatide (GLP-1 + GIP)

Tirzepatide is the active ingredient in Zepbound and Mounjaro, and Chia offers compounded tirzepatide tablets and injection, which are not FDA-approved, after a medical evaluation. Tirzepatide activates the GLP-1 receptor and the GIP receptor, which is why it is often called a dual incretin agonist 4.

In SURMOUNT-1, adults with obesity or overweight without diabetes received once-weekly tirzepatide. At 72 weeks, mean body-weight loss was 15.0% with 5 mg, 19.5% with 10 mg, and 20.9% with 15 mg, compared with 3.1% with placebo 2. Those are active-ingredient trial results, not proof of outcomes for any compounded formulation.

Side effects overlap with GLP-1 medicines: nausea, diarrhea, vomiting, constipation, stomach pain, and reduced appetite are common. The Zepbound label also carries warnings about thyroid C-cell tumors, pancreatitis, gallbladder disease, severe stomach problems, kidney injury, hypersensitivity reactions, and suicidal behavior or thinking; it is contraindicated with medullary thyroid carcinoma history, MEN2, or serious hypersensitivity to tirzepatide 4.

Where retatrutide fits (investigational)

Retatrutide is an investigational triple agonist that targets the GIP, GLP-1, and glucagon receptors. In a phase 2 trial, adults with obesity receiving the highest studied once-weekly dose had 24.2% mean weight loss at 48 weeks, versus 2.1% with placebo 5.

Retatrutide is not FDA-approved, is not available for prescribing, and cannot be legally compounded. Side effects in the phase 2 trial were mainly gastrointestinal and dose-related, and larger trials are needed to clarify safety, durability, and who should not use it 5. Chia does not offer retatrutide.

Which peptides only support weight loss without causing it?

Support peptides may affect sleep, recovery, growth-hormone signaling, or visceral fat in narrow settings. They should not be described as proven general weight-loss medicines.

Sermorelin and CJC-1295 / ipamorelin

Sermorelin is a growth-hormone-releasing hormone analog. CJC-1295 and ipamorelin are also used to stimulate the growth-hormone axis, though they do so through different receptors. These compounds are discussed in body-composition care because growth hormone helps regulate lean mass and fat metabolism 6.

Human evidence for broad weight loss is limited. Sermorelin has been studied as a diagnostic and growth-hormone-stimulation agent, and CJC-1295 has been shown to raise growth hormone and IGF-1 in healthy adults, but those studies were not large obesity weight-loss trials 6, 14. Chia offers compounded sermorelin in injection, nasal spray, and tablet forms for patients who qualify; compounded sermorelin is not FDA-approved, and we do not present it as a stand-alone fat-loss drug.

Possible risks include injection-site reactions, headache, flushing, fluid retention, tingling, joint discomfort, and changes in glucose handling. People with active cancer, uncontrolled diabetes, severe illness, or other hormone-sensitive risks need careful medical review before any growth-hormone-axis therapy 15.

Tesamorelin

Tesamorelin is a growth-hormone-releasing hormone analog with a narrow FDA-approved use: reduction of excess abdominal fat in adults with HIV and lipodystrophy. In a pivotal trial, tesamorelin reduced visceral adipose tissue by about 15% over 26 weeks, while placebo increased it by about 5% 7.

That does not make tesamorelin a general weight-loss peptide. Its approved use is for visceral adipose tissue in HIV lipodystrophy, not for general obesity or “belly fat” in otherwise healthy adults. Side effects can include injection-site reactions, joint pain, limb pain, swelling, muscle pain, glucose changes, and hypersensitivity; it is contraindicated in pregnancy and in people with active malignancy or disrupted hypothalamic-pituitary axis from pituitary surgery, pituitary tumor, hypopituitarism, head irradiation, or head trauma 8. Chia does not offer tesamorelin.

AOD-9604 and MOTS-c

AOD-9604 is a fragment related to human growth hormone. MOTS-c is a mitochondrial-derived peptide studied for metabolic signaling. Both are often marketed online for fat loss, but the human evidence is not close to the evidence base for semaglutide or tirzepatide.

For AOD-9604, published human data have not shown enough consistent weight-loss benefit to support broad use as an obesity medicine 9. For MOTS-c, much of the strongest work is preclinical; mouse studies suggest effects on insulin sensitivity and metabolic stress, but that is not the same as proven human weight loss 10. Side effects, product quality, and long-term safety are especially uncertain when these are purchased from no-prescription research vendors. Chia does not offer AOD-9604 or MOTS-c.

How do GLP-1 peptides compare with growth-hormone peptides?

GLP-1 medicines work mainly through appetite and fullness. Growth-hormone peptides work mainly through pituitary hormone signaling, so they may support body composition but should not be expected to match GLP-1 weight-loss trials 1, 2, 6.

How are peptides different from Ozempic?

Ozempic is a brand-name semaglutide product FDA-approved for type 2 diabetes, not a blanket term for all peptides. Semaglutide is a peptide-based GLP-1 receptor agonist, but many peptides have completely different targets 11.

Wegovy and Ozempic both contain semaglutide, but they have different labeled uses and dosing schedules. Wegovy’s obesity label includes a target maintenance dose of 2.4 mg once weekly after escalation, while Ozempic’s label is for type 2 diabetes and cardiovascular risk reduction in certain adults 3, 11.

Compounded semaglutide should not be called a generic Ozempic or generic Wegovy. It is a compounded medication prepared for an individual prescription by a licensed pharmacy; it is not FDA-approved, and the FDA does not evaluate compounded products for safety, effectiveness, or manufacturing quality before they are dispensed 12.

Do weight-loss peptides target belly fat specifically?

Belly fat is not usually lost on command. GLP-1 and GIP/GLP-1 medicines lower total body weight, and abdominal fat often falls as part of that larger change 1, 2.

Tesamorelin is the main peptide with a specific visceral-fat indication, but only for adults with HIV and lipodystrophy. Its trials measured visceral adipose tissue by imaging and found a meaningful reduction, but that evidence does not apply to general weight loss in the same way 7, 8.

For most people, the practical goal is total fat loss while protecting muscle. That means enough protein, resistance training, sleep, and a dose plan that a clinician adjusts slowly enough to reduce side effects. GLP-1 medicines can reduce lean mass along with fat during weight loss, so preserving strength is part of good care 13.

Are compounded weight-loss peptides safe?

Compounded medications can be an appropriate prescription path when they are ordered by a licensed provider and made by a state-licensed 503A pharmacy. The bigger safety divide is licensed medical care versus no-prescription research chemicals.

Under federal law, 503A compounding pharmacies prepare medications for individual patients based on valid prescriptions. Compounded drugs are not FDA-approved, and the FDA does not verify them the same way it reviews approved drug products 12.

A safer path includes a health history review, medication interaction check, side-effect plan, and follow-up access. Online peptide sellers that do not require a prescription may have problems with identity, purity, sterility, labeling, or dosing accuracy. That is especially risky for injectable products 12.

• Avoid no-prescription “research use only” products for self-injection.
• Tell your provider about pancreatitis, gallbladder disease, kidney disease, diabetes medicines, pregnancy plans, eating-disorder history, and thyroid cancer history.
• Ask how to report nausea, vomiting, dehydration, severe abdominal pain, mood changes, or allergic symptoms.
• Use provider-guided follow-up instead of changing dose or frequency on your own.

Who is a candidate, and who should not use weight-loss peptides?

Eligibility depends on BMI, health history, medicines, pregnancy status, and goals. A licensed provider must decide whether benefits outweigh risks.

FDA-approved obesity medicines are generally studied for adults with obesity, or adults with overweight plus at least one weight-related condition. Semaglutide and tirzepatide labels include specific BMI-based indications for chronic weight management 3, 4.

People may not be candidates for GLP-1 pathway medicines if they have certain thyroid cancer histories, MEN2, serious hypersensitivity to the drug, pregnancy, or a risk profile that makes side effects unsafe. Other cautions include pancreatitis history, gallbladder disease, severe GI disease, kidney disease, diabetes medicines that can cause low blood sugar, and some mental-health histories 3, 4.

For growth-hormone-axis peptides, extra caution is needed with active cancer, uncontrolled diabetes, edema, sleep apnea, or hormone-sensitive conditions. These peptides are not a shortcut around nutrition, movement, sleep, or medical review 8, 15.

How do you get weight-loss peptides through Chia?

At Chia, patients start with a short online health questionnaire. A licensed US provider reviews the information and prescribes only when clinically appropriate; a prescription is never guaranteed.

For weight-loss treatment, Chia offers semaglutide injection with plans currently starting at $249/month and tirzepatide tablets or injection, with tablet plans currently starting at $249/month and injection plans currently starting at $299/month. Microdosing plans are available for semaglutide and tirzepatide when a provider decides that a lower-dose titration approach fits the patient.

For patients focused on body composition, recovery, or lean-mass support during weight loss, Chia also offers sermorelin in injection, nasal spray, and tablets, with injection plans currently starting at $179/month. Some patients may be evaluated for the GLP-1 + Sermorelin protocol or the Weight + Energy protocol, depending on goals and provider review.

Medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door. Dosing is provider-guided and adjusted over time, and patients can message their care team through the patient portal between visits.

How should you choose your next step?

Your next step should match the evidence to your goal. If the goal is meaningful weight loss, GLP-1 pathway medicines have the strongest data; if the goal is recovery or lean-mass support, growth-hormone-axis peptides are a different conversation.

1. 1Start by naming the goal: total weight loss, appetite control, visceral-fat concern, muscle preservation, energy, or recovery.
2. 2Match the peptide to the evidence: semaglutide and tirzepatide for weight-loss evidence; tesamorelin only for its specific HIV lipodystrophy indication; sermorelin and related peptides for selected body-composition discussions.
3. 3Review risks before benefits: GI side effects, dehydration, gallbladder symptoms, pancreatitis warnings, thyroid cancer contraindications, glucose effects, and hormone-sensitive conditions.
4. 4Use a licensed provider and pharmacy pathway, not no-prescription research products.
5. 5Expect follow-up. The plan should change if side effects, labs, goals, or health history change.

Frequently asked questions

Keep reading

Weight Loss

Weight Loss Peptides: What Actually Works and What Does Not

Weight Loss

Peptide Injections for Weight Loss: What Actually Works

Peptides

Peptide Shots: What They Are, How They Work, and Who Should Consider Them